AdaptHealth (AHCO)
(Delayed Data from NSDQ)
$10.02 USD
-0.07 (-0.69%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $10.02 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.02 USD
-0.07 (-0.69%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $10.02 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
Zacks News
AHCO vs. LZAGY: Which Stock Is the Better Value Option?
by Zacks Equity Research
AHCO vs. LZAGY: Which Stock Is the Better Value Option?
Is AdaptHealth (AHCO) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AdaptHealth Corp. (AHCO) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AdaptHealth (AHCO) delivered earnings and revenue surprises of 10.53% and 0.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
by Zacks Equity Research
Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.
Implied Volatility Surging for AdaptHealth (AHCO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.
AHCO or PBH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AHCO vs. PBH: Which Stock Is the Better Value Option?
Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ
by Zacks Equity Research
KARL STORZ is set to acquire all of the outstanding shares of Asensus Surgical (ASXC) for $0.35 per share in cash, making Asensus a subsidiary of KARL STORZ.
AdaptHealth Corp. (AHCO) Lags Q1 Earnings Estimates
by Zacks Equity Research
AdaptHealth (AHCO) delivered earnings and revenue surprises of -66.67% and 2.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Lantheus Holdings (LNTH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 9.03% and 5.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Philips (PHG) Q1 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Philips' (PHG) first-quarter results benefit from strong momentum across the Diagnosis & Treatment and Personal Health businesses. However, softness in the Connected Care business is a concern.
AHCO vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AHCO vs. BSX: Which Stock Is the Better Value Option?
Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AdaptHealth Corp. (AHCO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
AHCO or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AHCO vs. BSX: Which Stock Is the Better Value Option?
Philips (PHG) Boosts Patient Monitoring With smartQare Deal
by Zacks Equity Research
Philips (PHG) partners with smartQare to integrate the latter's viQtor solution, boosting its patient monitoring solutions portfolio.
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
by Zacks Equity Research
Here is how AdaptHealth Corp. (AHCO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
AHCO vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AHCO vs. BSX: Which Stock Is the Better Value Option?
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
by Zacks Equity Research
Here is how AdaptHealth Corp. (AHCO) and Ascendis Pharma A/S (ASND) have performed compared to their sector so far this year.
AHCO vs. HLN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AHCO vs. HLN: Which Stock Is the Better Value Option?
Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AdaptHealth Corp. (AHCO) and Ascendis Pharma A/S (ASND) have performed compared to their sector so far this year.
Do Options Traders Know Something About AdaptHealth (AHCO) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.
AdaptHealth Corp. (AHCO) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of 45.45% and 3.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -30.77% and 15.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Soars 19.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AdaptHealth Corp. (AHCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Are Options Traders Betting on a Big Move in AdaptHealth (AHCO) Stock?
by Zacks Equity Research
Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.
Implied Volatility Surging for AdaptHealth (AHCO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.